1107693-22-0

Upstream product

• 951127-29-0 (2R,3S)-5-methylidenyl-3-nitro-2-(2,5-difluorophenyl)tetrahydro-2H-pyran 
• 951127-30-3 (2R,3S)-2-(2,5-difluorophenyl)-5-methylenetetrahydro-2H-pyran-3-amine 
• 951127-31-4 [(2R,3S)-5-methylene-2-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-yl]carbamic acid tert-butyl ester 
• 951127-25-6 N-[(2R,3S)-2-(2,5-difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester 
• 1107484-78-5 tert-butyl ((2R,3S,5S)-2-(2,5-difluorophenyl)-5-(pyrrolo[3,4-c]-pyrazol-5(1H,4H,6H)-yl)tetrahydro-2H-pyran-3-yl)carbamate 
• 1280210-79-8 2,6-dihydropyrrole [3,4-c]pyrazole-5(4H)-carboxylic acid tert-butyl ester 
• 951127-27-8 1-(2,5-difluorophenyl)-2-nitroethanone 
• 951127-28-9 6-(2,5-difluorophenyl)-3-methylidene-5-nitro-3,4-dihydro-2H-pyran 

Relevant academic research and scientific papers

Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2- (methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran- 3-amine (23)

A series of novel tri-2,3,5-substituted tetrahydropyran analogs were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the series provided inhibitors with good DPP-4 potency and selectivity over other peptidases (QPP, DPP8, and FAP). Compound 23, which is very potent, selective, efficacious in the diabetes PD model, and has an excellent pharmacokinetic profile, is selected as a clinical candidate.